Browsing by Author "Bhatia, Neha"
Now showing items 1-5 of 5
-
Developing our knowledge of the quinolone scaffold and its value to anticancer drug design
Singh, Yogesh; Bhatia, Neha; Biharee, Avadh; Kulkarni, Swanand; Thareja, Suresh; Monga, Vikramdeep (Taylor and Francis Ltd., 2023-08-18)Introduction: The quinolone scaffold is a bicyclic benzene-pyridinic ring scaffold with nitrogen at the first position and a carbonyl group at the second or fourth position. It is endowed with a diverse spectrum of ... -
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
Bhatia, Neha; Thareja, Suresh (Springer, 2023-05-16)Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu�. Elacestrant ... -
Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17?-hydroxysteroid dehydrogenase type 5 (17?-HSD5) inhibitors
Kulkarni, Swanand; Singh, Yogesh; Biharee, Avadh; Bhatia, Neha; Monga, Vikramdeep; Thareja, Suresh (Taylor and Francis Ltd., 2023-02-06)Excess of androgens leads to various diseases such as Poly-Cystic Ovarian Syndrome, Prostate Cancer, Hirsutism, Obesity and Acne. 17?-Hydroxysteroid Dehydrogenase type 5 (17?-HSD5) converts androstenedione into testosterone ... -
Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer
Bhatia, Neha; Khator, Rakesh; Kulkarni, Swanand; Singh, Yogesh; Kumar, Pradeep; Thareja, Suresh (Bentham Science Publishers, 2022-11-16)Discovery of MDM2 and MDM2-p53 interaction inhibitors changed the direction of anticancer research as it is involved in about 50% of cancer cases globally. Not on-ly the inhibition of MDM2 but also its interaction with p53 ... -
Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview
Bhatia, Neha; Hazra, Shreejita; Thareja, Suresh (Elsevier Masson s.r.l., 2023-05-04)Discovery of SERDs has changed the direction of anticancer research, as more than 70% of breast cancer cases are estrogen receptor positive (ER+). Therapies such as selective estrogen receptor modulators (SERM) and aromatase ...